
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Study Phase : Preclinical
Sponsor : 3PBiovian
Deal Size : Undisclosed
Deal Type : Collaboration
Eleva, 3PBIOVIAN Partner to Boost Capacity for Eleva’s Platform & Pipeline
Details : The collaboration aims to advance Factor H (CPV-104), a recombinant version of human complement Factor H, with a primary focus on delivering clinical data in C3 Glomerulopathy as the lead indication.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 04, 2025
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Highest Development Status : Preclinical
Sponsor : 3PBiovian
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eleva Doses Factor H Therapy In C3-Glomerulopathy To Healthy Volunteers
Details : The lead program, Factor H (CPV-104), a recombinant human complement Factor H, has entered a Phase 1/2 clinical studies to treat C3 Glomerulopathy (C3G).
Product Name : CPV-104
Product Type : Protein
Upfront Cash : Inapplicable
February 07, 2024
Lead Product(s) : Factor H
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
